When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.

Dr Sean C. McConnell provides an introduction to gene editing, and Scott J. Schweikart discusses what prudent governance requires.

This month, AMA Journal of Ethics theme editor Jacquelyn Nestor, a fifth-year MD/PhD student at Hofstra-Northwell School of Medicine, interviewed Allen Buchanan, PhD, about how we can safely explore cutting-edge biomedical enhancements.

Sterling Johnson joins Ethics Talk to discuss his article, coauthored with Dr Kimberly L. Sue: "Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies.”

Gene editing to enhance humans’ adaptability to climate change should consider safety, harm to be averted, succeeding generations, and social consequences.

Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients.

The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient.

Although parents may someday have the ability to enhance the complex physical and mental traits of their offspring, such genetic enhancements raise a number of difficult ethical questions.

Lack of ethical, legal, and clinical consensus about best practice sometimes combines with a poor clinical evidence base.

Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions.